About two years ago, a head-to-head progression-free survival win made Akeso and Summit Therapeutics’ ivonescimab—and the ...
Novartis is taking social media by storm with a multiple sclerosis (MS) campaign that urges patients to #KnowYourMS, a ...
While a positive advisory committee meeting seemed to up the odds of approval for Replimune’s twice-snubbed melanoma drug in ...
Repatha, also known as evolocumab, was first approved by the FDA in 2015 to help patients lower their LDL, or “bad,” ...
Following a string of customer complaints, a Form 483 and a recall this past spring, a Fresenius manufacturing unit in Utah ...
CMI Media Group is adding to its spread of media services through a new specialty communications business that introduces a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results